Lamivudine , ≥99% , 134678-17-4

Synonym(s):
Lamivudine;Epivir;Epivir-HBV;Heptovir;Zeffix

CAS NO.：134678-17-4

Empirical Formula: C8H11N3O3S

Molecular Weight: 229.26

MDL number: MFCD00869739

EINECS: 603-844-3

PRODUCT Properties

• Melting point: 177 °C
• Boiling point: 475.4±55.0 °C(Predicted)
• alpha: D21 -135° (c = 0.38 in methanol)
• Density: 1.73±0.1 g/cm3(Predicted)
• refractive index: -142 ° (C=1, MeOH)
• Flash point: 9℃
• storage temp.: 2-8°C
• solubility: water: soluble10mg/mL, clear
• pka: 13.83±0.10(Predicted)
• form: powder
• color: white to beige
• Water Solubility: 70g/L(temperature not stated)
• Merck: 14,5352
• BCS Class: 1,3
• Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
• InChIKey: JTEGQNOMFQHVDC-NKWVEPMBSA-N

Description and Uses

Lamivudine is a new generation orally active nucleoside analog launched in the U.S.A. for use in combination with zidovudine (AZT) as a first-line therapy for patients with HIV infection. Lamivudine is rapidly converted to phosphorylated metabolites in the body which act as inhibitors and chain terminators of HIV reverse transcriptase (RT), the enzyme required for the replication of the HIV genome. Lamivudine has similar inhibitory potency to RT as AZT but is 10 times less toxic and is active against AZT-resistant strains of HIV.

Lamivudine (Epivir-HBV) is in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). It works by decreasing the amount of HIV and hepatitis B in the blood. It is used to treat hepatitis B infection. It is also used along with other medications to treat human immunodeficiency virus (HIV) infection in adults and children 3 months of age and older.

Safety

• Symbol(GHS): GHS08
• Signal word: Warning
• Hazard statements: H361
• Precautionary statements: P280
• Risk Statements: 63-36/37/38
• Safety Statements: 26-36
• RIDADR: UN1230 - class 3 - PG 2 - Methanol, solution
• WGK Germany: 3
• RTECS: UW7361333
• HS Code: 29349990